Bioharvest Financials
Bioharvest (BHST) reported $34.5M in revenue for fiscal year 2025, up 37.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Gross-margin expansion is improving unit economics, but external financing still carries the business while cash burn persists.
From FY2023 to FY2025, revenue nearly tripled while gross margin climbed from44.5% to59.3% , so each new dollar of sales is contributing more before overhead. But free cash flow stayed pinned near-$9.6M even as EBITDA losses narrowed, meaning better product economics have not yet become self-funding cash generation.
Cash reached
Over two years, gross profit increased by about
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Bioharvest's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Bioharvest, and counted as zero in the overall score.
Not available for Bioharvest, and counted as zero in the overall score.
Bioharvest passes 3 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 2 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Bioharvest reported a net loss of $11.1M while operations used $7.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Bioharvest generated $34.5M in revenue in fiscal year 2025. This represents an increase of 37.0% from the prior year.
Bioharvest's EBITDA was -$4.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 31.1% from the prior year.
Bioharvest reported -$11.1M in net income in fiscal year 2025. This represents an increase of 13.8% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Bioharvest recorded an outflow of $9.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 0.7% from the prior year.
Bioharvest held $23.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Bioharvest's gross margin was 59.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 4.0 percentage points from the prior year.
Bioharvest's operating margin was -16.2% in fiscal year 2025, reflecting core business profitability. This is up 11.6 percentage points from the prior year.
Bioharvest's net profit margin was -32.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 19.0 percentage points from the prior year.
Bioharvest's ROE was -43.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 927.1 percentage points from the prior year.
Capital Allocation
Bioharvest invested $2.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 16.9% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
BHST Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Revenue | $34.5M+37.0% | $25.2M+98.8% | $12.7M |
| Cost of Revenue | $14.0M+24.8% | $11.2M+59.8% | $7.0M |
| Gross Profit | $20.5M+46.9% | $13.9M+147.5% | $5.6M |
| Operating Income | -$5.6M+20.2% | -$7.0M+29.9% | -$10.0M |
| Income Tax | -$76K-850.0% | -$8K | $0 |
| Net Income | -$11.1M+13.8% | -$12.9M-2.8% | -$12.6M |
Not reported in any period shown, so not listed: R&D Expenses, SG&A Expenses, Interest Expense, EPS (Diluted).
BHST Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Current Assets | $30.5M+288.2% | $7.9M-13.2% | $9.1M |
| Cash & Equivalents | $23.0M+863.4% | $2.4M-55.4% | $5.4M |
| Inventory | $4.6M+24.7% | $3.7M+48.2% | $2.5M |
| Accounts Receivable | $2.0M+77.5% | $1.1M+38.1% | $808K |
| Current Liabilities | $7.7M-46.1% | $14.3M-46.1% | $26.5M |
| Total Equity | $25.4M+1813.4% | $1.3M+109.0% | -$14.9M |
| Retained Earnings | -$107.6M-11.5% | -$96.4M-15.5% | -$83.5M |
Not reported in any period shown, so not listed: Total Assets, Goodwill, Total Liabilities, Long-Term Debt.
BHST Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Operating Cash Flow | -$7.2M-8.1% | -$6.7M+21.6% | -$8.5M |
| Capital Expenditures | $2.4M-16.9% | $2.8M+92.3% | $1.5M |
| Free Cash Flow | -$9.6M-0.7% | -$9.5M+4.8% | -$10.0M |
| Investing Cash Flow | -$2.4M+21.9% | -$3.0M-105.4% | -$1.5M |
| Financing Cash Flow | $30.2M+345.2% | $6.8M-50.0% | $13.6M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BHST Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Gross Margin | 59.3%+4.0pp | 55.4%+10.9pp | 44.5% |
| Operating Margin | -16.2%+11.6pp | -27.8%+50.9pp | -78.6% |
| Net Margin | -32.3%+19.0pp | -51.3%+47.9pp | -99.2% |
| Return on Equity | -43.8%+927.1pp | -970.9% | N/A |
| Current Ratio | 3.97+3.4x | 0.55+0.2x | 0.34 |
| FCF Margin | -27.8%+10.0pp | -37.8%+41.1pp | -78.9% |
Not reported in any period shown, so not listed: Return on Assets, Debt-to-Equity.
Similar Companies
Where Bioharvest Ranks
Frequently Asked Questions
What is Bioharvest's annual revenue?
Bioharvest (BHST) reported $34.5M in total revenue for fiscal year 2025. This represents a 37.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bioharvest's revenue growing?
Bioharvest (BHST) revenue grew by 37.0% year-over-year, from $25.2M to $34.5M in fiscal year 2025.
Is Bioharvest profitable?
No, Bioharvest (BHST) reported a net income of -$11.1M in fiscal year 2025, with a net profit margin of -32.3%.
What is Bioharvest's EBITDA?
Bioharvest (BHST) had EBITDA of -$4.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Bioharvest's gross margin?
Bioharvest (BHST) had a gross margin of 59.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bioharvest's operating margin?
Bioharvest (BHST) had an operating margin of -16.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Bioharvest's net profit margin?
Bioharvest (BHST) had a net profit margin of -32.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Bioharvest's return on equity (ROE)?
Bioharvest (BHST) has a return on equity of -43.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bioharvest's free cash flow?
Bioharvest (BHST) recorded an outflow of $9.6M in free cash flow during fiscal year 2025. This represents a -0.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bioharvest's operating cash flow?
Bioharvest (BHST) recorded an outflow of $7.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Bioharvest's capital expenditures?
Bioharvest (BHST) invested $2.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Bioharvest's current ratio?
Bioharvest (BHST) had a current ratio of 3.97 as of fiscal year 2025, which is generally considered healthy.
What is Bioharvest's cash runway?
Based on fiscal year 2025 data, Bioharvest (BHST) had $23.0M in cash against an annual operating cash burn of $7.2M. This gives an estimated cash runway of approximately 38 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Bioharvest's Piotroski F-Score?
Bioharvest (BHST) has a Piotroski F-Score of 3 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bioharvest's earnings high quality?
Bioharvest (BHST) reported a net loss of $11.1M while operations used $7.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Bioharvest?
Bioharvest (BHST) scores 39 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.